Skip to main content

Table 1 Pooled baseline characteristics for the semaglutide trials

From: Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

 

CVOTsa

Glycemic efficacy trialsb

Overall

Semaglutide

Placebo

Semaglutide

Comparatorc

Semaglutide

Comparatorc

n = 3,239

n = 3,241

n = 7,269

n = 3,896

n = 10,508

n = 7,137

CV risk score

−1.0 (0.6)

−0.9 (0.6)

−1.7 (0.6)

−1.7 (0.6)

−1.5 (0.7)

−1.4 (0.7)

Age, years

65.3 (7.2)

65.5 (7.4)

57.5 (10.4)

57.5 (10.6)

59.9 (10.2)

61.1 (10.1)

HbA1c, %

8.4 (1.5)

8.4 (1.6)

8.2 (0.9)

8.2 (0.9)

8.3 (1.1)

8.3 (1.2)

Smoking status, n (%)

 Current smoker

388 (12.0)

367 (11.3)

1,254 (17.3)

667 (17.1)

1,642 (15.6)

1,034 (14.5)

 Never smoked

1,473 (45.5)

1,457 (45.0)

3,946 (54.3)

2,153 (55.3)

5,419 (51.6)

3,610 (50.6)

 Previous smoker

1,378 (42.5)

1,417 (43.7)

2,069 (28.5)

1,076 (27.6)

3,447 (32.8)

2,493 (34.9)

LDL-C, mmol/L

2.2 (0.9)

2.3 (0.9)

2.7 (0.9)

2.7 (0.9)

2.6 (0.9)

2.5 (0.9)

Pulse rate, bpm

71.6 (11.1)

71.5 (11.1)

74.2 (10.5)

74.3 (10.5)

73.4 (10.7)

73.0 (10.9)

Systolic BP, mmHg

135.7 (17.5)

135.5 (17.2)

132.2 (14.7)

132.3 (15.1)

133.3 (15.7)

133.8 (16.2)

Heart failured, n (%)

564 (17.4)

586 (18.1)

349 (4.8)

212 (5.4)

913 (8.7)

798 (11.2)

 NYHA

      

  Class Id

91 (2.8)

97 (3.0)

155 (2.1)

93 (2.4)

246 (2.3)

190 (2.7)

  Class II

404 (12.5)

419 (12.9)

177 (2.4)

115 (3.0)

581 (5.5)

534 (7.5)

  Class III

69 (2.1)

70 (2.2)

17 (0.2)

4 (0.1)

86 (0.8)

74 (1.0)

Prior ischemic heart disease, n (%)

1,403 (43.3)

1,430 (44.1)

850 (11.7)

491 (12.6)

2,253 (21.4)

1,921 (26.9)

Prior MI, n (%)

1,091 (33.7)

1,131 (34.9)

307 (4.2)

185 (4.7)

1,398 (13.3)

1,316 (18.4)

Prior stroke, n (%)

363 (11.2)

412 (12.7)

199 (2.7)

117 (3.0)

562 (5.3)

529 (7.4)

Insulin use, n (%)

1,740 (53.7)

1,722 (53.1)

869 (12.0)

374 (9.6)

2,609 (24.8)

2,096 (29.4)

eGFR,e ml/min/1.73 m2

75.0 (21.8)

75.1 (22.1)

94.8 (17.1)

94.3 (17.9)

88.7 (20.8)

85.6 (22.1)

  1. Data are mean (SD) unless otherwise stated
  2. aCVOTs included SUSTAIN 6 and PIONEER 6.
  3. bGlycemic efficacy trials included SUSTAIN 1–5, the SUSTAIN Japanese trials, PIONEER 1–5 and PIONEER 7–10.
  4. cComparators included placebo, sitagliptin, exenatide ER, insulin glargine, dulaglutide, liraglutide and empagliflozin; for details of the n, (%) and observation times for each comparator see Additional file 3: Appendix Table S3.
  5. dThe PIONEER 6 trial did not capture data on subjects with NYHA Class I.
  6. eeGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration formula.
  7. BP blood pressure, bpm beats per minute, CV cardiovascular, CVOT cardiovascular outcomes trial, eGFR estimated glomerular filtration rate, exenatide ER exenatide extended release, HbA1c glycated hemoglobin, LDL-C low-density lipoprotein cholesterol, MI myocardial infarction, NHYA New York Heart Association, SD standard deviation
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840